4 results

• Familial PSP

  Cases of PSP that occur in multiple members of the same family, suggesting a hereditary component.

  Reference:

  Donker Kaat L, Boon AJ, Azmani A, et al. Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology. 2009;73(2):98-105. doi:10.1212/WNL.0b013e3181a92bcc

• FNP-223

  Investigational, brain-penetrant, selective OGA inhibitor intended as a potential DMT for PSP.

  Reference:

  Permanne B, Sand A, Ousson S, et al. O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for tau and α-synuclein proteinopathies. ACS Chem Neurosci. 2022;13(8):1296-1314. doi:10.1021/acschemneuro.2c00057

• Frontal cognitive/behavioral presentation

  Defined as at least three of the following features, which have to be persistent: apathy; bradyphenia; dysexecutive syndrome; reduced phonemic verbal fluency; impulsivity, disinhibition, or perseveration.

  Reference:

  Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987

• Frontal dysfunction

  Impairment of the frontal lobe, which affects executive, cognitive, or behavioral functions.

  Reference:

  Pirau L, Lui F. Frontal lobe syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532981/